Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Kioxia Holdings | Tempus AI | |
|---|---|---|
| Moat rating | narrow Kioxia's FY2025 Annual Securities Report (dated 2026-06-24) describes a real but bounded position. It records 'the limited number of major competitors in the flash memory business', and says its three manufacturing joint ventures with Sandisk let it 'make investments on a larger scale than if it were to invest alone and enjoy economies of scale in terms of capital expenditures and production efficiency'. Against that, the same Risk Factors section describes 'heavy global competition as advanced technologies are necessary for business execution', says 'in the flash memory market the Group's ability to decide prices is limited', that 'Some competitors possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group', and records that the Group cut production from October 2022 to March 2024. Scale in a small field, not a barrier that protects Kioxia's returns through the cycle. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | cost scale The advantage the company itself names is scale and capital efficiency. The Annual Securities Report says the Sandisk joint ventures, which procure the production equipment installed at Kioxia's Yokkaichi and Kitakami plants and 'sell 50% of their products to the Group and 50% to the Sandisk Group', let it 'enjoy economies of scale in terms of capital expenditures and production efficiency'. At its 2026 Investor Day (2026-06-02) management said that 'by leveraging our world-leading economies of scale, we have maintained a lower cost per gigabyte than the industry average', on a slide that cites the TechInsights NAND Market Report Q2 2026 as its source. The filing describes its technology work (layer stacking for BiCS FLASH, the move to QLC) and names 'a decline in competitiveness in production efficiency per gigabyte' as a risk if it falls behind. It does not present that technology as protected IP that rivals cannot match. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | at parity TrendForce's 2Q26 NAND Flash ranking (2026-08-18) puts Kioxia fourth with revenue of about $10.72 billion. Its 13.6% share 'edged down', and it sits behind Samsung (29.3%), SK hynix Group and Micron, which moved up to third. TrendForce's 2Q26 enterprise SSD ranking (2026-09-01) also places it fourth, at $4.64 billion. On technology it is keeping pace: it began sampling the 332-layer 10th-generation BiCS FLASH on 2026-07-03, per its press release. The Annual Securities Report concedes that some competitors 'possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group'. Kioxia is in the middle of a small group of peers. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | weak The Annual Securities Report states that 'in the flash memory market the Group's ability to decide prices is limited, and in the medium- to long-term selling prices on a bit basis may decline at a similar pace as in the past'. Current margins follow the market. The first-quarter FY2026 results attribute the revenue jump primarily to 'a significant increase in average selling prices (ASPs) resulting from strong demand from data center customers focusing on generative AI'. Gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. In the 2026 Investor Day Q&A management said it believes 'market pricing will continue to reflect those supply-demand conditions'. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | Kioxia calls itself 'a specialized flash memory manufacturer'. It makes BiCS FLASH 3D NAND at Yokkaichi and Kitakami in Japan through three manufacturing joint ventures with Sandisk, whose output is sold 50% to Kioxia and 50% to Sandisk. FY2025 (year to March 2026) revenue was ¥2,337.6bn: SSD & Storage ¥1,362.6bn, Smart Devices ¥760.0bn and Other ¥215.0bn, with the Apple group alone at 20.4% of sales. Its moat is scale in a concentrated industry. TrendForce ranks it fourth in 2Q26 NAND revenue with a 13.6% share, and in August 2026 the partners announced anticipated investments in Japan of over $31 billion through 2032, contingent on government support. The same filing sets out the limits: limited ability to set prices; rivals that also make DRAM and have more financial strength; China's government-supported push for domestic semiconductor production; and a joint-venture agreement effective until 2034, with no decision yet on whether it continues after that. First-quarter FY2026 gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. The company attributes the jump primarily to a significant increase in average selling prices. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | Upstream NAND flash and SSD supplier. The filing says much of its revenue 'depends on a limited number of customers and industries, such as major smartphone manufacturers and large IT companies, including hyperscalers that require SSDs'. The Apple group was 20.4% of FY2025 sales. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |